Zakia Belaid-Sandal
CEO/CSO Theranovir
Seminars
Wednesday 28th January 2026
Disrupting DDR Signaling by Targeting Leptin-Dependent NRP-1/ OBR with NOV2 to Overcome Resistance & Induce Chromosomal Instability
2:30 pm
- See how Theranovir is developing NOV2, a monoclonal antibody targeting the Leptin-dependent NRP-1/OBR complex involved in DDR signaling and nuclear translocation
- Sharing preclinical data demonstrating NOV2’s ability to induce chromosome instability, including centromere disruption and telomere shortening
- Exploring NOV2’s potential to overcome resistance and relapse, and its future use in combination with immune checkpoint inhibitors
